Alumis (ALMS) Stock Price, News & Analysis

Company Overview

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Key Stats

• Today's Range: $5.00 to $5.49
• 50-Day Range: $3.57 to $10.07
• 52-Week Range: $3.18 to $13.53
• Volume: 294,951 shs
• Average Volume: 325,220 shs
• Market Capitalization: $247.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.86
• Consensus Rating: Buy

Alumis Stock Analysis - MarketRank™

Alumis scored higher than 53% of companies evaluated by MarketBeat, and ranked 511th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Alumis has received a consensus rating of Buy. The company's average rating score is 3.22, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Alumis has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alumis are expected to grow in the coming year, from ($8.51) to ($4.19) per share.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ALMS.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alumis does not currently pay a dividend.

Dividend Growth

Alumis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ALMS.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.54

News Sentiment

Alumis has a news sentiment score of 1.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Alumis this week, compared to 4 articles on an average week.

Search Interest

Only 3 people have searched for ALMS on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.

MarketBeat Follows

3 people have added Alumis to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Alumis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,891,895.00 in company stock and sold $0.00 in company stock.

ALMS Stock Analysis - Frequently Asked Questions

How have ALMS shares performed this year?

Alumis' stock was trading at $7.86 at the beginning of 2025. Since then, ALMS shares have decreased by 33.1% and is now trading at $5.2550.
View the best growth stocks for 2025 here.

When did Alumis IPO?

Alumis (ALMS) raised $210 million in an initial public offering on Friday, June 28th 2024. The company issued 13,125,000 shares at $16.00 per share.

Who are Alumis' major shareholders?

Top institutional investors of Alumis include Towerview LLC (0.91%), Charles Schwab Investment Management Inc. (0.27%), BML Capital Management LLC (0.11%) and Bank of New York Mellon Corp (0.09%).
View institutional ownership trends.

How do I buy shares of Alumis?

Shares of ALMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Alumis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alumis investors own include Comstock (LODE), Ashford Hospitality Trust (AHT), Artificial Intelligence Technology Solutions (AITX), Allakos (ALLK), BioXcel Therapeutics (BTAI), Clearside Biomedical (CLSD) and Delcath Systems (DCTH).

Company Calendar

• Today: 5/12/2025
• Next Earnings (Estimated): 6/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALMS
• Previous Symbol: NASDAQ:ALMS
• CIK: 1847367
• Web: N/A
• Phone: (650) 231-6625
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $25.86
• High Stock Price Target: $36.00
• Low Stock Price Target: $13.00
• Potential Upside/Downside: +392.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.22
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.26
• Quick Ratio: 11.26

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 47,222,000
• Free Float: N/A
• Market Cap: $248.15 million
• Optionable: N/A
• Beta: N/A